With governments experiencing resource constraints, payers consolidating, and technology rapidly expanding, healthcare companies are competing to create the care models of the future in both emerging and developed markets. The opportunities for private industry are vast, but choosing the right market segments, payers, and patients to commercialize your therapeutics, devices, and services has never been more crucial.
Ensure that your science and intellectual property prevail in complex markets with a multidisciplinary approach that blends macro insights, payer and patient intelligence, competitive awareness, and channel strategies.
DuckerFrontier serves a range of executives in the healthcare industry, from the companies that develop the pharmaceuticals and medical technology to the clinics and hospitals that use them. Our clients include firms on the cutting edge of pharmaceuticals, biopharmaceuticals, medical devices, and diagnostics; payers; hospital systems; and private equity.
We combine analysis and forecasting of macro trends, including government spending power and operating conditions in specific geographies, with evaluations of the segments to target in those geographies to provide a comprehensive view of market opportunity.
We provide a 360-degree assessment of the geographic and market-specific barriers you need to overcome to commercialize your therapeutics, including the regulatory environment, competitive landscape, patient/provider/payer insights, and channel options.
We provide industry benchmarks on the provision of value-added services around core therapeutics/devices and build strategies to help you protect and grow market share in an increasingly competitive, price-constrained environment.
We help you make the right strategic choices in a rapidly consolidating industry by mapping acquisition targets and conducting due diligence, including your targets’ ability to achieve growth and market access goals.
We host the leading conferences for market research and competitive intelligence professionals in the pharmaceutical and healthcare industry, bringing together thought leaders and influencers from leading companies for interactive discussions.
In the US, the adoption of value-based care payments is expected to reach
by 2020 (Aetna 2018 Healthcare Trends)
including 70% of the largest 20 Fortune 500 pharmaceutical and medical device companies
of multinational pharmaceutical companies do not have value-added services that contribute to profitability growth; the figure is 46% for medical device multinationals (DuckerFrontier healthcare executive survey, 2018)
countries covered with data, analysis, consulting engagements, expert insights, and reports
client projects completed in pharmaceuticals and medical devices in the last four years